首页> 美国卫生研究院文献>Biomarker Research >IGH amplification in patients with B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and Burkitt’s lymphoma
【2h】

IGH amplification in patients with B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and Burkitt’s lymphoma

机译:B细胞淋巴瘤患者的IGH扩增无法分类其特征介于弥漫性大B细胞淋巴瘤和Burkitt淋巴瘤之间

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

B cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt’s lymphoma (BL) (B-UNC/BL/DLBCL) is a new category of tumors that have features resembling both DLBCL and BL. These tumors have large and medium sized cells with greater irregularity of nuclei and more prominent nucleoli than BL. Approximately 35% to 50% have C-MYC rearrangements, although half are non-immunoglobulin variants. We identified six cases of B-UNC/BL/DLBCL with low-level IGH amplification. Four patients died with a median survival of 7 months (range, 6–20). In conclusion, to our knowledge low-level IGH amplification has not been previously described and should be evaluated for in this patient population.
机译:B细胞淋巴瘤是无法分类的,其特征介于弥漫性大B细胞淋巴瘤(DLBCL)和伯基特淋巴瘤(BL)(B-UNC / BL / DLBCL)之间,是一类具有类似于DLBCL和BL特征的新型肿瘤。这些肿瘤具有大中型细胞,其细胞核不规则性更大,核仁比BL大。大约35%至50%具有C-MYC重排,尽管一半是非免疫球蛋白变体。我们鉴定出六例低水平IGH扩增的B-UNC / BL / DLBCL病例。四名患者死亡,中位生存期为7个月(范围6-20)。总而言之,据我们所知,以前没有描述过低水平的IGH扩增,应该对此患者人群进行评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号